Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

Abstract Cerebral gliomas of World Health Organization (WHO) grade II and III represent a major challenge in terms of histological classification and clinical management. Here, we asked whether large-scale genomic and transcriptomic profiling improves the definition of prognostically distinct entities. We performed microarray-based genome- and transcriptome-wide analyses of primary tumor samples from a prospective German Glioma Network cohort of 137 patients with cerebral gliomas, including 61 WHO grade II and 76 WHO grade III tumors. Integrative bioinformatic analyses were employed to define molecular subgroups, which were then related to histology, molecular biomarkers, including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation, 1p/19q co-deletion and telomerase reverse transcriptase (TERT) promoter mutations, and patient outcome. Genomic profiling identified five distinct glioma groups, including three IDH1/2 mutant and two IDH1/2 wild-type groups. Expression profiling revealed evidence for eight transcriptionally different groups (five IDH1/2 mutant, three IDH1/2 wild type), which were only partially linked to the genomic groups. Correlation of DNA-based molecular stratification with clinical outcome allowed to define three major prognostic groups with characteristic genomic aberrations. The best prognosis was found in patients with IDH1/2 mutant and 1p/19q co-deleted tumors. Patients with IDH1/2 wild-type gliomas and glioblastoma-like genomic alterations, i...
Source: Acta Neuropathologica - Category: Neurology Source Type: research

Related Links:

Publication date: Available online 16 October 2019Source: Journal of Photochemistry and Photobiology B: BiologyAuthor(s): Deborah Piffaretti, Floriana Burgio, Marcus Thelen, Alain Kaelin-Lang, Paolo Paganetti, Michael Reinert, Maria Luisa D'AngeloAbstractFluorescence image guided surgical resection (FIGR) of high grade gliomas (HGGs) takes advantage of the accumulation of the tracer protoporphyrin IX (PpIX) in glioma cells following administration of 5-aminolevulinic acid (5-ALA). Occasionally, PpIX fluorescence intensity may be insufficient, thus compromising the efficacy and precision of the surgical intervention. The ca...
Source: Journal of Photochemistry and Photobiology B: Biology - Category: Speech-Language Pathology Source Type: research
Contributors : Chen-Xue Mao ; Zhao-Qian LiuSeries Type : Expression profiling by array ; Non-coding RNA profiling by arrayOrganism : Homo sapiensAstrocytoma is a common pathologic type of glioma, its survival and prognosis remain poor.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Non-coding RNA profiling by array Homo sapiens Source Type: research
Nano LettersDOI: 10.1021/acs.nanolett.9b03968
Source: Nano Letters - Category: Nanotechnology Authors: Source Type: research
ConclusionTogether VEGF levels and angiogenic capacity in CSF can be used as a biological marker of gliomas malignancy.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 15 October 2019Source: Life SciencesAuthor(s): He Li, Yin Luo, Luojiang Zhu, Weilong Hua, Yongxin Zhang, Hongjian Zhang, Lei Zhang, Zifu Li, Pengfei Xing, Yongwei Zhang, Bo Hong, Pengfei Yang, Jianmin LiuAbstractGlia is an important component of the nervous system that is involved in neurotransmitter uptake, signal transduction, myelin synthesis, neurodevelopment, and immune response. Exosomes are extracellular vesicles that are secreted from certain types of cells, and are known to mediate glia function. Glia-derived exosomes (GDEs) can transport proteins, nucleotides and cellular waste,...
Source: Life Sciences - Category: Biology Source Type: research
Malignant glioma is one of the essentially incurable tumors with chemoresistance and tumor recurrence. As a histone methyltransferase, SUV39H2 can trimethylate H3K9. SUV39H2 is highly expressed in many types o...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
ConclusionThe strongest determinant of the patients ’ course after initial watchful waiting was the molecular tumor status. Extensive resection may increase time to progression and malignant transformation. Observation may be justified in selected patients.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to clarify the survival in adult patients.MethodsWe utilized the SEER database (1973 –2015) to analyze the association between survival and demographic data, tumor characteristics, and treatment factors in adult patients with brainstem HGGs. Patients without surgical intervention were excluded. Overall survival (OS) was analyzed using univariable and multivariable Cox regression.ResultsOur dataset included a total of 502 brainstem HGG patients of which only those who had undergone surgical intervention were included in the analysis, totaling 103. Mean age was 42.4  ± 14.1 years w...
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
AbstractMolecular genetic aberrations in the phosphoinositide 3 ‐kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway are common in human cancers including glioblastoma, yet, novel therapeutic approaches targeting this pathway in glioblastoma have not been successful. We hypothesized that molecular profiling in combination with in vitro drug sensitivity testing allows to identify signatures associated with sensitivity or resistance to PI3K/mTOR pathway inhibition. We analyzed the molecular mechanisms determining sensitivity to PI3K/mTOR inhibition using gene silencing or pharmacological targe...
Source: Journal of Neurochemistry - Category: Neuroscience Authors: Tags: Original Article Source Type: research
Glioblastoma (GB) represents the most frequent primary malignancy of the brain in adults, accounting for more than half of all gliomas [1]. Survival times are still narrow and range between 1 and 3  years [2–6]. Even patients with favorable risk factors, such as young age, high Karnofsky performance status (KPS) and hypermethylation of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter suffer from tumor recurrence, usually occurring 14–17 months after therapy [2,6].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
More News: Brain Tumor | Genetics | Glioma | Health | International Medicine & Public Health | Molecular Biology | Neurology | WHO